|
|
Assay Validation of High-Quality Markers for Clinical Studies in Cancer
NCI invites applications to support the validation of molecular/cellular/imaging markers (referred to as "markers" or "biomarkers") and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. This NOFO supports investigator-initiated research for both analytical and clinical validation of assays to be used in cancer treatment, control, or prevention trials supported by NCI.
This NOFO is to accelerate the adoption and validation of molecular/cellular/imaging markers (referred to as "markers" or "biomarkers") and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. This also supports the validation of pharmacodynamic markers (molecular indicators of drug effect on the target in an organism) and markers of toxicity.
Pancreatic Cancer Detection Consortium: Research Units
NCI is soliciting applications for the Research Units, one of the two scientific components of the Pancreatic Cancer Detection Consortium, to conduct research on early detection of pancreatic ductal adenocarcinoma and characterization of its precursor lesions to identify those patients who are at high risk of progression to cancer.
|
Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research
NCI encourages applications that propose to advance research in cancer etiology and early detection biomarkers, utilizing the advantages of the unique biorepository resources of the NCI-sponsored Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial. The PLCO Biorepository offers high-quality, prospectively collected, serial pre-diagnostic blood samples from the PLCO-screened arm participants, and a one-time collection of buccal cells from both the screened and the control arm participants. Available data associated with the biospecimens includes demographic, diet, lifestyle, smoking, screening results, and other clinical data.
Expires 10/12/2024
Imaging, Biomarkers, and Digital Pathomics for the Early Detection of Premetastatic Cancer and Precancerous Lesions Associated with Lethal Phenotypes
NCI supports the development of state-of-the-art projects that integrate imaging, biomarkers, digital pathomics, glycomics, metabolomics, other -omic information and/or meta data obtained from platforms including but not limited to lower resolution diagnostic acquisitions and systemic biomarker results to high resolution single-cell analytics/imaging applied to the characterization of heterogeneous cell populations within tumor for improving current approaches for: (1) the early detection of organ confined premetastatic aggressive cancer, and, (2) identifying precancerous lesions associated with the development of a subsequent lethal phenotype. This NOFO specifically attempts to address and improve diagnostic uncertainty in clinical decisions by improving detection sensitivity and specificity of integrated multiparametric platforms.
|
|
|
“Cancer Prevention with Resistant Starch in Lynch Syndrome Patients” Lecture on July 17, at 10:00 a.m. ET
John C. Mathers, Ph.D., of Newcastle University, U.K., will be giving a lecture via Zoom on “Cancer Prevention with Resistant Starch in Lynch Syndrome Patients,” on Monday, July 17 at 10:00 a.m., ET.
Dr. Mathers is a principal investigator for a portfolio of research projects in the areas of nutrition and the prevention of complex diseases including colon cancer, cardiovascular disease, and dementia. His work includes studies on the biological basis of aging and ranges from molecular and cell biological studies, through investigations in human volunteers to nutritional epidemiology and large-scale intervention studies.
Latest News
Results from two NCI-supported studies relating to symptom management were among the significant findings presented at the June 2023 Annual Meeting of the American Society of Clinical Oncology (ASCO). The study results, which both incorporated data from patient-reported outcomes (PROs), have the potential to help reduce toxic side effects and improve quality of life for people with cancer.
|
|
|
|
|
|
